Inventor · disambiguated record
Ruben J. Boado
Also filed as: BOADO RUBEN J
28 granted patents·20 pending applications·574 citations·filing 1991–2025
97Inventor score
Files withARMAGEN INC21PARDRIDGE WILLIAM M13ARMAGEN TECHNOLOGIES INC6UNIV CALIFORNIA5ARMAGEN TECH INC2
Top patents by PatentIndex Score
48 records- 0197US7741446B2Fusion antibodies that cross the blood-brain barrier in both directionsARMAGEN TECHNOLOGIES INC·Filed 2007·Granted Jun 22, 2010·83 cites·17 claims
- 0296US8497246B2Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositionsPARDRIDGE WILLIAM M·Filed 2007·Granted Jul 30, 2013·34 cites·15 claims
- 0395US8834874B2Methods and compositions for increasing iduronate 2-sulfatase activity in the CNSPARDRIDGE WILLIAM M·Filed 2010·Granted Sep 16, 2014·22 cites·16 claims
- 0495US8753610B2Methods for diagnosing CNS disorders with fusion antibodies that cross the blood-brain barrier in both directionsPARDRIDGE WILLIAM M·Filed 2010·Granted Jun 17, 2014·23 cites·23 claims
- 0595US8741260B2Fusion proteins for delivery of GDNF to the CNSPARDRIDGE WILLIAM M·Filed 2008·Granted Jun 3, 2014·15 cites·23 claims
- 0695US8124095B2Fusion proteins for delivery of erythropoietin to the CNSPARDRIDGE WILLIAM M·Filed 2010·Granted Feb 28, 2012·32 cites·22 claims
- 0795US8053569B2Nucleic acids encoding and methods of producing fusion proteinsARMAGEN TECHNOLOGIES INC·Filed 2005·Granted Nov 8, 2011·36 cites·58 claims
- 0894US8715661B2Methods and compositions for increasing arylsulfatase A activity in the CNSARMAGEN TECHNOLOGIES INC·Filed 2013·Granted May 6, 2014·20 cites·26 claims
- 0994US8142781B2Fusion proteins for blood-brain barrier deliveryPARDRIDGE WILLIAM M·Filed 2005·Granted Mar 27, 2012·29 cites·93 claims
- 1094US7388079B2Delivery of pharmaceutical agents via the human insulin receptorUNIV CALIFORNIA·Filed 2002·Granted Jun 17, 2008·46 cites·6 claims
- 1193US8920801B2Methods and compositions for increasing arylsulfatase A activity in the CNSARMAGEN TECHNOLOGIES INC·Filed 2014·Granted Dec 30, 2014·17 cites·20 claims
- 1293US8759297B2Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cnsPARDRIDGE WILLIAM M·Filed 2007·Granted Jun 24, 2014·17 cites·23 claims
- 1393US8486399B2Methods and compositions for increasing arylsulfatase A activity in the CNSPARDRIDGE WILLIAM M·Filed 2012·Granted Jul 16, 2013·16 cites·19 claims
- 1493US6287792B1Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technologyUNIV CALIFORNIA·Filed 1991·Granted Sep 11, 2001·137 cites·4 claims
- 1591US12043661B2Methods and compositions for increasing iduronate 2-sulfatase activity in the CNSARMAGEN INC·Filed 2021·Granted Jul 23, 2024·1 cites·10 claims
- 1691US11155631B2Macromolecular compositions that cross the blood-brain barrier and methods of use thereofARMAGEN INC·Filed 2015·Granted Oct 26, 2021·4 cites·5 claims
- 1791US10538589B2Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLUARMAGEN INC·Filed 2016·Granted Jan 21, 2020·4 cites·10 claims
- 1891US2024327507A1Methods and compositions for increasing iduronate 2-sulfate activity in the cnsARMAGEN INC·Filed 2024·Application pending·0 cites
- 1990US8974791B2Methods and compositions for increasing α-L-iduronidase activity in the CNSPARDRIDGE WILLIAM M·Filed 2008·Granted Mar 10, 2015·10 cites·13 claims
- 2088US11512145B2Methods and compositions for increasing alpha-L-iduronidase activity in the CNSARMAGEN INC·Filed 2019·Granted Nov 29, 2022·2 cites·11 claims
- 2187US2024409650A1Methods and compositions for increasing n-acetylglucosaminidase activity in the cnsARMAGEN INC·Filed 2024·Application pending·0 cites
- 2286US10144783B2Macromolecular compositions that cross the blood-brain barrier and methods of use thereofARMAGEN INC·Filed 2014·Granted Dec 4, 2018·5 cites·22 claims
- 2384US10011651B2Methods and compositions for increasing iduronate 2-sulfatase activity in the CNSARMAGEN INC·Filed 2014·Granted Jul 3, 2018·4 cites·32 claims
- 2483US11028156B2Methods and compositions for increasing iduronate 2-sulfatase activity in the CNSARMAGEN INC·Filed 2018·Granted Jun 8, 2021·1 cites·14 claims
- 2583US8858950B2Delivery of pharmaceutical agents via the human insulin receptorPARDRIDGE WILLIAM M·Filed 2008·Granted Oct 14, 2014·4 cites·8 claims
- 2682US10202467B2Methods and compositions for increasing α-L-iduronidase activity in the CNSARMAGEN INC·Filed 2017·Granted Feb 12, 2019·2 cites·4 claims
- 2782US9533055B2Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteinsPARDRIDGE WILLIAM M·Filed 2010·Granted Jan 3, 2017·5 cites·1 claims
- 2882US2023279156A1Methods and compositions for increasing alpha-l-iduronidase activity in the cnsARMAGEN INC·Filed 2022·Application pending·0 cites
- 2981US9975955B2Methods and compositions for increasing arylsulfatase A activity in the CNSARMAGEN INC·Filed 2014·Granted May 22, 2018·3 cites·16 claims
- 3077US2022378932A1Fusion proteins for delivery of gdnf to the cnsARMAGEN INC·Filed 2022·Application pending·0 cites
- 3176US2022348672A1Methods and compositions for increasing enzyme activity in the cnsARMAGEN INC·Filed 2022·Application pending·0 cites
- 3276US2022127369A1Methods and compositions for increasing n-acetylglucosaminidase activity in the cnsARMAGEN INC·Filed 2022·Application pending·0 cites
- 3374US10906981B2Compositions and methods related to structures that cross the blood brain barrierUNIV CALIFORNIA·Filed 2014·Granted Feb 2, 2021·1 cites·15 claims
- 3469US2020254113A1Fusion proteins for delivery of gdnf to the cnsARMAGEN INC·Filed 2020·Application pending·0 cites
- 3568US2021002379A1Methods and compositions for increasing n-acetylglucosaminidase activity in the cnsARMAGEN INC·Filed 2020·Application pending·0 cites
- 3667US9567400B2Methods and compositions for increasing α-L-iduronidase activity in the CNSARMAGEN TECH INC·Filed 2015·Granted Feb 14, 2017·1 cites·31 claims
- 3766US2020308292A1Methods and compositions for increasing enzyme activity in the cnsARMAGEN INC·Filed 2020·Application pending·0 cites
- 3864US2014193409A1Fusion proteins for delivery of gdnf to the cnsARMAGEN TECHNOLOGIES INC·Filed 2013·Application pending·0 cites
- 3963US2025179201A1Methods and compositions for increasing galactosidase beta-1 activity in the cnsARMAGEN INC·Filed 2025·Application pending·0 cites
- 4060US2010077498A1Compositions and methods for blood-brain barrier delivery in the mousePARDRIDGE WILLIAM M·Filed 2009·Application pending·0 cites
- 4160US2008051564A1Delivery of pharmaceutical agents via the human insulin receptorUNIV CALIFORNIA·Filed 2007·Application pending·0 cites
- 4259US2021403584A1Methods and compositions for increasing galactosidase beta-1 activity in the cnsARMAGEN INC·Filed 2020·Application pending·0 cites
- 4358US2015023956A1Methods and compositions for increasing enzyme activity in the cnsARMAGEN TECHNOLOGIES INC·Filed 2014·Application pending·0 cites
- 4453US2010098693A1Compositions and methods for blood-brain barrier delivery of organophosphatasesPARDRIDGE WILLIAM M·Filed 2009·Application pending·0 cites
- 4551US2024252667A1Methods and compositions for increasing the activity in the cns of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1ARMAGEN INC·Filed 2019·Application pending·0 cites
- 4649US2003165853A1Antisense imaging of gene expression of the brain in vivoUNIV CALIFORNIA·Filed 2001·Application pending·0 cites
- 4746US2005202075A1Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainersFiled 2004·Application pending·0 cites
- 4841US2017066832A1Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteinsARMAGEN TECH INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ruben J. Boado files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →